Humanigen

OverviewSuggest Edit

Humanigen (formerly known as KaloBios) is repositioning and developing its proprietary monoclonal antibodies to meet some critical unmet needs in cancer science. The Company's focus is on making chimeric antigen receptor T-cell (CAR-T) therapy safer, better and more routine. Its lead asset lenzilumab is poised to begin testing for possible prophylaxis of neurotoxicity and cytokine release syndrome related to CAR-T treatment.

TypePublic
Founded2000
HQBurlingame, CA, USMap
Websitehumanigen.com

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)2(-33%)
Share Price (Dec 2020)$9.1 (-4%)
Cybersecurity ratingAMore

Key People/Management at Humanigen

Cameron Durrant

Cameron Durrant

Chairman & CEO
Dale Chappell

Dale Chappell

Chief Scientific Officer
Edward P. Jordan

Edward P. Jordan

Chief Commercial Officer
Omar Ahmed

Omar Ahmed

SVP. Clinical, Medical and Scientific Affairs
Timothy Morris

Timothy Morris

Chief Operating and Financial Officer
David Tousley

David Tousley

Chief Accounting and Administrative Officer, Corp Secretary and Treasurer
Show more

Humanigen Office Locations

Humanigen has offices in Burlingame and Kansas City
Burlingame, CA, US (HQ)
533 Airport Blvd #400
Kansas City, MO, US
900 W 48th Pl #900, Kansas City
Show all (2)

Humanigen Financials and Metrics

Humanigen Revenue

USD

Net income (Q2, 2020)

(24.0m)

EBIT (Q2, 2020)

(23.1m)

Market capitalization (1-Dec-2020)

490.4m

Closing stock price (1-Dec-2020)

9.1

Cash (30-Jun-2020)

41.7m
Humanigen's current market capitalization is $490.4 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

14.3m8.4m7.9m9.1m6.3m

R&D expense

16.7m10.4m11.2m2.2m2.6m

Operating expense total

34.4m18.8m19.0m11.3m8.9m

EBIT

(34.4m)(18.8m)(19.0m)(11.3m)(8.9m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

1.2m2.5m2.5m2.4m1.5m2.0m4.0m2.0m1.8m1.9m1.7m1.5m1.4m2.0m

R&D expense

1.7m4.4m1.7m2.7m3.9m3.8m696.0k577.0k535.0k359.0k1.2m549.0k659.0k21.1m

Operating expense total

2.9m6.9m4.2m5.1m5.4m5.8m4.7m2.6m2.3m2.2m3.0m2.0m2.1m23.1m

EBIT

(2.9m)(6.9m)(4.2m)(5.1m)(5.4m)(5.8m)(4.7m)(2.6m)(2.3m)(2.2m)(3.0m)(2.0m)(2.1m)(23.1m)
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

8.4m2.9m737.0k814.0k143.0k

Prepaid Expenses

2.0m1.6m813.0k485.0k309.0k

Current Assets

10.4m4.5m1.6m1.3m452.0k

PP&E

288.0k68.0k19.0k
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

6.6m11.9m2.9m4.0m103.0k1.1m1.6m267.0k2.0m180.0k1.1m157.0k68.0k41.7m

Prepaid Expenses

1.7m1.3m1.8m1.7m1.5m1.2m838.0k665.0k504.0k479.0k425.0k366.0k293.0k770.0k

Current Assets

8.3m13.3m4.7m5.7m1.7m2.3m2.4m932.0k2.5m659.0k1.5m523.0k361.0k42.5m

PP&E

170.0k145.0k121.0k53.0k41.0k30.0k10.0k
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(35.4m)(27.0m)(22.0m)(12.0m)(10.3m)

Depreciation and Amortization

197.0k102.0k48.0k19.0k

Accounts Payable

2.5m4.5m(520.0k)(198.0k)2.2m

Cash From Operating Activities

(29.1m)(21.0m)(14.2m)(6.2m)(4.0m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(5.4m)(17.4m)(22.0m)(5.5m)(11.7m)(18.9m)(5.1m)(7.8m)(9.9m)(2.5m)(5.9m)(8.3m)(2.5m)(26.5m)

Depreciation and Amortization

33.0k58.0k81.0k14.0k27.0k38.0k10.0k19.0k19.0k

Accounts Payable

3.2m4.6m3.5m(507.0k)(434.0k)327.0k(28.0k)(88.0k)(159.0k)592.0k717.0k1.1m860.0k(2.9m)

Cash From Operating Activities

(2.0m)(9.0m)(17.9m)(4.4m)(8.3m)(12.3m)(1.8m)(3.7m)(5.0m)(684.0k)(2.3m)(3.5m)(607.0k)(22.6m)
show all
USDFY, 2015

Financial Leverage

1.9 x
Show all financial metrics

Humanigen Operating Metrics

FY, 2015FY, 2016FY, 2017

Patent Applications

69 26 17

Patents (Foreign)

37 64 42

Patents (US)

7 23 18
Show all operating metrics

Humanigen Acquisitions / Subsidiaries

Company NameDateDeal Size
Celscia Therapeutics
KaloBios

Humanigen Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

Learn more about our premium products
SecurityScorecard logo

Humanigen Online and Social Media Presence

Humanigen's Trends

Embed Graph

Humanigen News and Updates

May 31, 2019

Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (axicabtagene ciloleucel) With lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

-- Phase 1/2 Multi-Center Clinical Trial to Begin Enrolling in Q4 2019 -- -- Phase 1/2 Multi-Center Clinical Trial to Begin Enrolling in Q4 2019 --
March 21, 2019

Humanigen Data Presented at the 2019 National Comprehensive Cancer Network (NCCN) Annual Conference Demonstrates Potential to Improve the Efficacy of CAR-T Therapy

BURLINGAME, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (OTCQB: HGEN) (“Humanigen”) a biopharmaceutical company focused on the development of its proprietary Humaneered® monoclonal antibodies focused on chimeric antigen receptor T (CAR-T) cell therapy optimization and immuno-oncolo…
November 02, 2018

Humanigen Announces Lenzilumab Study Results Accepted as Oral Presentation at the 2018 Annual Meeting of the American Society of Hematology (ASH)

Study Demonstrates that GM-CSF Neutralization with Lenzilumab in Combination with Chimeric Antigen Receptor T (CAR-T) Cell Therapy Prevents the Onset of Cytokine Release Syndrome, Significantly Reduces the Severity of Neurotoxicity and Improves CAR-T Proliferation and Effector Functions …

 Humanigen Frequently Asked Questions

  • When was Humanigen founded?

    Humanigen was founded in 2000.

  • Who are Humanigen key executives?

    Humanigen's key executives are Cameron Durrant, Dale Chappell and Edward P. Jordan.

  • How many employees does Humanigen have?

    Humanigen has 2 employees.

  • Who are Humanigen competitors?

    Competitors of Humanigen include Intrexon, Abcam and XOMA.

  • Where is Humanigen headquarters?

    Humanigen headquarters is located at 533 Airport Blvd #400, Burlingame.

  • Where are Humanigen offices?

    Humanigen has offices in Burlingame and Kansas City.

  • How many offices does Humanigen have?

    Humanigen has 2 offices.